Literature DB >> 19669348

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

Yi-Cheng Chen1, Chia-Ming Chu, Chau-Ting Yeh, Yun-Fan Liaw.   

Abstract

PURPOSE: To elucidate the long-term natural course following the onset of cirrhosis in patients with chronic hepatitis B.
METHODS: Ninety-three patients with chronic hepatitis B who had developed cirrhosis during regular follow-up were included in this long-term follow-up study. At the time of cirrhosis detection, 30% of the patients were seropositive for hepatitis B e antigen (HBeAg) and 73% had a HBV-DNA level >10(4) copies/ml. Follow-up studies included liver biochemistry, viral markers, alpha-fetoprotein and ultrasonography every 3-6 months.
RESULTS: During a mean follow-up period of 102 +/- 60 (12-246; median 97) months, 32 patients (34.4%) experienced 55 episodes of hepatitis flare (7.0%/year), 15 (53.6%) of 28 HBeAg-positive patients seroconverted to anti-HBe (6.3%/yr) and 12 (12.9%) lost HBsAg (1.5%/year). Overall disease progression was observed in 25 (26.9%, 3.2%/year) patients: 12 (12.9%, 1.5%/year) hepatic decompensation, 21 (22.6%, 2.7%/year) hepatocellular carcinoma and 11 (11.8%, 1.4%/year) died. Multivariate analysis showed that age at onset of cirrhosis (P = 0.015) and persistent HBeAg seropositivity (P = 0.019) were the independent factors for overall disease progression.
CONCLUSIONS: These results suggest that patients with older age at onset of cirrhosis and persistent HBeAg seropositivity following the onset of cirrhosis were independent factors for the disease progression in the first 10-year after the development of cirrhosis in patients with chronic hepatitis B.

Entities:  

Year:  2007        PMID: 19669348      PMCID: PMC2720722          DOI: 10.1007/s12072-007-5001-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  22 in total

1.  Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.

Authors:  Kenji Ikeda; Yasuji Arase; Masahiro Kobayashi; Takashi Someya; Satoshi Saitoh; Yoshiyuki Suzuki; Fumitaka Suzuki; Akihito Tsubota; Norio Akuta; Hiromitsu Kumada
Journal:  Intervirology       Date:  2003       Impact factor: 1.763

2.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.

Authors:  Giovanna Fattovich; Maurizio Pantalena; Irene Zagni; Giuseppe Realdi; Solko W Schalm; Erik Christensen
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

3.  Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.

Authors:  Alex Yui Hui; Henry Lik-yuen Chan; Nancy Wai-yee Leung; Lawrence Cheung-tsui Hung; Francis Ka-leung Chan; Joseph Jao-yiu Sung
Journal:  J Clin Gastroenterol       Date:  2002 May-Jun       Impact factor: 3.062

Review 4.  Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy.

Authors:  Yun-Fan Liaw
Journal:  J Gastroenterol Hepatol       Date:  2003-03       Impact factor: 4.029

5.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Authors:  Y F Liaw; D I Tai; C M Chu; T J Chen
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

7.  Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.

Authors:  Yi-Cheng Chen; I-Shyan Sheen; Chia-Ming Chu; Yun-Fan Liaw
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 8.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

9.  Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Authors:  Y F Liaw; D Y Lin; T J Chen; C M Chu
Journal:  Liver       Date:  1989-08

10.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology.

Authors:  A S Lok; C L Lai
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

View more
  32 in total

1.  Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.

Authors:  Weixia Ke; Chi Zhang; Li Liu; Yanhui Gao; Zhenjiang Yao; Xiaohua Ye; Shudong Zhou; Yi Yang
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

2.  Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.

Authors:  Keng Lai; Chi Zhang; Weixia Ke; Yanhui Gao; Shudong Zhou; Li Liu; Yi Yang
Journal:  Clin Drug Investig       Date:  2017-03       Impact factor: 2.859

Review 3.  Management of HBV and HBV/HDV-Associated Liver Cirrhosis.

Authors:  Christoph Höner Zu Siederdissen; Markus Cornberg
Journal:  Visc Med       Date:  2016-04-12

Review 4.  Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.

Authors:  Koichi Honda; Masataka Seike; Kazunari Murakami
Journal:  World J Hepatol       Date:  2015-10-08

Review 5.  Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.

Authors:  Francesco Paolo Russo; Kryssia Rodríguez-Castro; Laura Scribano; Giorgia Gottardo; Veronica Vanin; Fabio Farinati
Journal:  World J Hepatol       Date:  2015-05-18

6.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

Review 7.  Does antiviral therapy reduce complications of cirrhosis?

Authors:  Goh Eun Chung; Jeong-Hoon Lee; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 8.  Virus-related liver cirrhosis: molecular basis and therapeutic options.

Authors:  Ji Lin; Jian-Feng Wu; Qi Zhang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.

Authors:  Myron John Tong; Carlos Hsien; Joanna Jungeun Song; Jia Horng Kao; Hai-En Sun; Leeyen Hsu; Steven-Huy Han; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.